Co-principal investigator Dan Theodorescu is the director of Cedars-Sinai Cancer Center and a renowned physician scientist and cancer expert. Theodorescu combines molecular and cell biology with computational methods in his research. He and Kuhn have long held a belief that convergent science holds exceptional power to find cancer solutions.

Co-principal investigator Christina Curtis of Stanford University brings extensive biomedical data science expertise. Using the latest computational methods, she’ll lead efforts to parse the copious and varied information the consortium researchers will produce.


Co-investigator Fariba Navid of Children’s Hospital Los Angeles has expertise in pediatric bone and soft tissue sarcomas. She will continue an ongoing collaboration with Kuhn to assess circulating tumor cells in these cancers.

The establishment of the Convergent Science Cancer Consortium, much of which is modeled on the recently established Convergent Science Virtual Cancer Center led by Theodorescu as director and Kuhn as deputy director, marks a pivotal moment in cancer research, according to the researchers — one that “means new avenues of hope for patients and their families,” said Kuhn.

Back to HCB News

Rad Oncology Homepage